drugset / Trial / NCT06552260
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Phase 0
Recruiting
27 enrolled
Ugonma Chukwueke
Biohaven Pharmaceuticals, Inc. · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
Timeline
- Start
- 2025-02-19
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Troriluzole | Peptide | 100 mg | Oral |